U.S. Markets open in 3 hrs 4 mins

Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Akebia Therapeutics Inc (AKBA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia Therapeutics Inc has a market cap of $1.02 billion; its shares were traded at around $8.73 with and P/S ratio of 1.90. Akebia Therapeutics Inc had annual average EBITDA growth of 19.90% over the past five years.


For the last quarter Akebia Therapeutics Inc reported a revenue of $59.9 million, compared with the revenue of $87.32 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $207.7 million, an increase of 16.7% from last year. For the last five years Akebia Therapeutics Inc had an average revenue decline of 0% a year.

The reported loss per diluted share was $1.471 for the year, compared with the loss per share of $8.04 in the previous year. The Akebia Therapeutics Inc had an operating margin of -85.75%, compared with the operating margin of -44.9% a year before. The 10-year historical median operating margin of Akebia Therapeutics Inc is -4467.40%. The profitability rank of the company is 3 (out of 10).

At the current stock price of $8.73, Akebia Therapeutics Inc is traded at 49.3% discount to its historical median P/S valuation band of $17.21. The P/S ratio of the stock is 1.90, while the historical median P/S ratio is 3.76. The stock lost 17.73% during the past 12 months.

For the complete 20-year historical financial data of AKBA, click here.

This article first appeared on GuruFocus.